Chronic Myeloid Leukemia Clinical Trials

A listing of Chronic Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 152 clinical trials
Nilotinib for First-line Newly Diagnosed CML-CP Patients

diagnosed chronic-phase chronic myeloid leukemia (CML-CP) in China. Nilotinib 300 mg BID will be provided in this study. The assessment for the primary efficacy endpoint will be performed at 18 months and

  • 9 views
  • 16 Feb, 2022
  • 1 location
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML

that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph

philadelphia chromosome
prednisone
dasatinib
male sterilization
gilbert's syndrome
  • 10 views
  • 15 Feb, 2022
  • 6 locations
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.

  • 1 views
  • 02 Feb, 2021
  • 1 location
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludarabine, cyclophosphamide and in some cases thiotepa) and radiation therapy. Giving chemotherapy and total-body irradiation before …

blast cells
graft versus host disease
bone marrow procedure
hematologic malignancy
serum bilirubin level
  • 10 views
  • 26 May, 2022
  • 1 location
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML

bosutinib
imatinib
asciminib
complete hematologic response
ponatinib
  • 1 views
  • 23 Jul, 2022
  • 8 locations
  • 0 views
  • 27 May, 2022
  • 1 location
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML), to preliminary estimate the safety and tolerability and efficacy, and

absolute neutrophil count
graft versus host disease
hydroxyurea
anagrelide
leukemia
  • 0 views
  • 10 Jul, 2022
  • 44 locations
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML

kinase inhibitor
leukemia
nilotinib
asciminib
tyrosine
  • 0 views
  • 22 Jul, 2022
  • 1 location
KISS Study: Kinase Inhibition With Sprycel Start up

Chronic myeloid leukaemia (CML) is due to a chromosomal abnormality in white blood cells which results in abnormal multiplication. CML in its earlier, slower growing chronic phase (CP) is well

hydroxyurea
remission
imatinib
leukemia
chronic phase chronic myeloid leukemia
  • 653 views
  • 20 Mar, 2021
  • 9 locations
Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis (BosuPeg)

myeloid leukemia patients, and to estimate efficacy of the addition of RoPegIFN to BOS in terms of deep molecular response with the aim of increasing the proportion of patients who may achieve treatment

interferon
anagrelide
hydroxyurea
leukemia
remission
  • 1 views
  • 27 Apr, 2022
  • 5 locations